executive_compensation

Accuray Grants New Services SVP 1.3M Inducement Stock Units

Image
Accuray Grants New Services SVP 1.3M Inducement Stock Units

Madison – October 31, 2026 -- Accuray Incorporated (NASDAQ: ARAY) granted 650,000 restricted stock units and 650,000 performance-based restricted stock units (at target) to Sofiane Laoussadi, its new Senior Vice President, Global Services & Solutions. The two awards cover 1.3 million shares of common stock at target.

Awards fall under NASDAQ inducement rule 5635(c)(4)

The Compensation Committee approved the grants as a material inducement for Laoussadi to join the company, in line with NASDAQ Listing Rule 5635(c)(4). Accuray disclosed them as that rule requires. Both awards took effect on October 30, 2026.

The grants sit outside the company's current equity plan. Their terms are generally consistent with those of the 2026 Equity Incentive Plan.

Actinium Grants Inducement Awards to New CFO and BD Chief

Image
Actinium Grants Inducement Awards to New CFO and BD Chief

New York – October 17, 2026 -- Actinium Pharmaceuticals (NYSE American: ATNM) granted new CFO Matt David, M.D., options on 250,000 shares at $0.97 each, plus 250,000 restricted stock units (RSUs) and up to 75,000 milestone-based RSUs, as inducement for joining the company.

CFO package combines options, time-based RSUs and milestone awards

The October 17, 2026 grant gives Dr. David a non-qualified stock option with a ten-year term. The $0.97 exercise price equals Actinium's closing price on the NYSE American that day.

Twenty-eight percent of the option vests on the first anniversary of the grant. The remainder vests in monthly installments of 2% over the following 36 months.

Of the 250,000 RSUs, 125,000 vest in three equal annual installments on the first, second and third anniversaries. The other 125,000 vest in full on the third anniversary. A further 75,000 RSUs, at most, vest only if specified corporate milestones are met.

Rigel Pharmaceuticals Grants 35,275 RSUs to 18 New Hires

Image
Rigel Pharmaceuticals Grants 35,275 RSUs to 18 New Hires

South San Francisco, Calif. – October 02, 2026 -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) has granted 35,275 restricted stock units to 18 non-executive employees under its Inducement Plan.

Rigel ties new hire equity to four-year vesting schedule

The restricted stock units vest over four years, with 25% of each grant releasing annually. The Compensation Committee of Rigel's Board of Directors approved the awards as an inducement material to new employees joining the company.

Grants comply with Nasdaq Listing Rule 5635(c)(4)

Rigel issued the awards in accordance with Nasdaq Listing Rule 5635(c)(4), which permits companies to grant equity inducements to new employees outside shareholder-approved equity plans. The rule requires public disclosure of such grants, which Rigel has now made.

MP Materials CEO Litinsky Tops 2026 Mining Pay Rankings at $28M

Image
MP Materials CEO Litinsky Tops 2026 Mining Pay Rankings at $28M

Toronto – October 01, 2026 -- MP Materials Founder, Chairman and CEO James Litinsky recorded fiscal 2025 total compensation of US$28.0 million (C$39.2 million), the highest figure in Bedford Group/TRANSEARCH's 2026 mining compensation rankings.

Litinsky's $28.0 Million Pay Package Tops Bedford's 2026 Mining Rankings

The package was weighted heavily toward long-term equity: US$24.8 million (C$34.6 million) in stock awards and US$2.2 million (C$3.1 million) in annual non-equity incentive compensation, against a base salary of US$1.0 million (C$1.4 million). Litinsky has led MP Materials since its founding in 2017, making the figure a long-tenured-CEO outcome rather than a new-hire package.

Dolby Grants New CEO Marc Whitten $10M in Stock, Performance RSUs Tied to $175 Share Price

Image
Dolby Grants New CEO Marc Whitten $10M in Stock, Performance RSUs Tied to $175 Share Price

San Francisco – September 19, 2026 -- Dolby Laboratories, Inc. (NYSE: DLB) has granted incoming President and Chief Executive Officer Marc Whitten inducement equity awards worth approximately $10 million in time-based restricted stock, plus a performance package that vests only if Dolby's share price climbs as high as $175.

Dolby ties CEO pay to five escalating stock-price hurdles

The compensation package, disclosed under Dolby's newly adopted 2026 Inducement Stock Plan, splits into two components. The first is a time-based award of 160,256 restricted stock units, valued at roughly $10 million using the average closing price of Dolby's Class A shares over the 30 trading days preceding the grant date. Those units vest semi-annually over two years, contingent on Whitten remaining employed at Dolby through each vesting date.

Sectra Shareholders Approve SEK 2.30 Dividend, New Incentive Plan at AGM

Linköping – – September 12, 2026 -- Shareholders of Sectra AB (STO:SECTB) approved a combined dividend of SEK 2.30 per share at the medical imaging IT and cybersecurity company's Annual General Meeting held September 8, 2026.

Sectra sets record date for SEK 2.30 combined payout

The AGM resolved to distribute an ordinary dividend of SEK 1.30 per share plus an extraordinary dividend of SEK 1.00 per share, with remaining funds carried forward. The record date is September 10, 2026, and payment through Euroclear Sweden AB is expected September 15, 2026.

Insmed Grants Equity Awards to 128 New Hires Under Nasdaq Inducement Plan

Image
Insmed Grants Equity Awards to 128 New Hires Under Nasdaq Inducement Plan

Bridgewater, N.J. – September 09, 2026 -- Insmed Incorporated (Nasdaq: INSM) has issued inducement equity awards to 128 newly hired employees, a move tied to its ongoing workforce expansion in the biopharmaceutical sector.

Insmed grants 115,320 restricted stock units to new hires as employment inducement

The awards, approved by Insmed's Compensation Committee, were granted on September 09, 2026, under the company's 2025 Inducement Plan. The plan is structured to comply with Nasdaq Listing Rule 5635(c)(4), which permits equity grants as a material inducement for new employees without requiring shareholder approval.